Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Novartis AG Stock (NVS) Moved Down by 3.61% on Oct 23: Facts Behind the Movement

Source Tradingkey

Novartis AG (NVS) moved down by 3.61%. The Pharmaceuticals & Medical Research sector is down by 1.37%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Moderna Inc (MRNA) up 1.57%; Eli Lilly and Co (LLY) down 1.93%; Johnson & Johnson (JNJ) down 1.79%.

SummaryOverview

What is driving Novartis AG (NVS)’s stock price down today?

Novartis AG experienced downward price action and elevated intraday volatility, primarily driven by broader market risk-off sentiment and cautious position adjustments ahead of its upcoming quarterly earnings release. Global equity indices faced broader selling pressure, which extended into large-cap healthcare and pharmaceutical equities. At the same time, market participants trimmed exposure as investors re-evaluated commercial growth projections amid ongoing structural revenue headwinds for key legacy blockbusters, particularly Entresto, which faces increasing patent expiry and generic entry pressures.

Recent pipeline updates and clinical presentations also factored heavily into intraday sentiment. Novartis held dedicated investor discussions while presenting detailed Phase III trial data for remibrutinib in relapsing multiple sclerosis at the joint MSToronto conference, alongside long-term six-year survival data for Kisqali at the ESMO congress. While clinical data confirmed therapeutic efficacy, market expectations remained high. In the wake of earlier R&D setbacks, including the recent discontinuation of a mid-stage trial for Fabhalta in lupus nephritis, several institutional investors opted to take profits and manage risk rather than expand positions following the clinical readouts.

Looking forward, institutional focus centers on the company's ability to replace mature revenue streams through newly authorized products such as Rhapsido and the continued global rollout of its expanded immunology and oncology franchises. With consensus analyst sentiment leaning cautious ahead of the upcoming financial results, near-term share price direction will largely depend on executive commentary regarding full-year margin targets, commercial scaling for newly launched therapies, and forward guidance on pipeline delivery.

Technical Analysis of Novartis AG (NVS)

Technically, Novartis AG (NVS) shows a MACD (12,26,9) value of 2.538, indicating a buy signal. The RSI at 55.996 suggests neutral condition and the Williams %R at 36.679 suggests buy condition. Please monitor closely.

Fundamental Analysis of Novartis AG (NVS)

Novartis AG (NVS) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $56.33B, ranking 9 in the industry. The net profit is $13.98B, ranking 5 in the industry. Company Profile

FundamentalAnalysis

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $153.26, a high of $185.00, and a low of $121.16.

More details about Novartis AG (NVS)

Company Specific Risks:

Pipeline Strategic Setbacks: Novartis recently discontinued its Phase 2 clinical trial evaluating iptacopan (Fabhalta) in lupus nephritis due to strategic considerations and trial performance, dampening investor expectations for expanding its high-margin renal and immunology drug pipeline.
Entresto Patent Erosion and Top-Line Headwinds: Institutional analysts are voicing concern over sharp revenue declines in core cardiovascular treatments, with U.S. Entresto sales dropping significantly year-over-year due to generic competition, creating revenue compression ahead of earnings.
Shareholder Litigation and Disclosure Investigations: The company faces active securities fraud investigations from class-action law firms following the failed Phase III HARBOR study of del-desiran, maintaining legal overhang and heightened regulatory disclosure scrutiny.
Sequential Earnings Compression Concerns: Wall Street consensus forecasts Q3 2026 earnings per share of $2.25, down from $2.41 in the prior quarter, driving institutional caution and position trimming ahead of the upcoming earnings report.

Source

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Dollar presses 102 as the 10-year yield sits at 5.14% — and October hike odds are only 17%The dollar index closed at 101.99 (+0.20%) on Monday after briefly topping 102.07, while the 10-year Treasury yield rose to 5.14% and the 2-year hit 4.774% — yet futures price only about a 17% chance of a hike at the October 27-28 FOMC, versus roughly 90% for December. The driver is a global bond selloff, not a Fed repricing: France's 10-year OAT jumped to 4.84% ~ 4.94% and the OAT-Bund spread widened to 140 ~ 146bp. Here are the levels, the cross-asset read-through and what to watch.

Author Irene Q.

Oct 20, Tue

The dollar index closed at 101.99 (+0.20%) on Monday after briefly topping 102.07, while the 10-year Treasury yield rose to 5.14% and the 2-year hit 4.774% — yet futures price only about a 17% chance of a hike at the October 27-28 FOMC, versus roughly 90% for December. The driver is a global bond selloff, not a Fed repricing: France's 10-year OAT jumped to 4.84% ~ 4.94% and the OAT-Bund spread widened to 140 ~ 146bp. Here are the levels, the cross-asset read-through and what to watch.

Meta's AI bill just hit $145 billion — and it issued a new share class to pay for it Meta reported record third-quarter revenue of $64.60 billion, up 26% from a year earlier, and raised full-year 2026 capital expenditure guidance to $135-145 billion from $130-145 billion. To fund that build-out without touching Mark Zuckerberg's voting control, the company announced a 2-for-1 stock split that hands every Class A holder a new non-voting Class C share. Here are the four lines that matter, the peer group that is being re-rated alongside it, and the bull and bear cases.

Author Irene Q.

Oct 22, Thu

Meta reported record third-quarter revenue of $64.60 billion, up 26% from a year earlier, and raised full-year 2026 capital expenditure guidance to $135-145 billion from $130-145 billion. To fund that build-out without touching Mark Zuckerberg's voting control, the company announced a 2-for-1 stock split that hands every Class A holder a new non-voting Class C share. Here are the four lines that matter, the peer group that is being re-rated alongside it, and the bull and bear cases.

The Fed will sit still on October 28 — but 100 of 100 economists now expect a December hike A Reuters poll run October 16-20 found 94 of 100 economists expecting the Fed to hold at 3.75-4.00% on October 28 — and all 100 expecting a hike in December, against less than half a month earlier. The market is close to the same price, with CME FedWatch at roughly 17% for October and 82.8% for December. With the Fed in blackout since October 17, here are the five dates that decide the rest of the year, what each one is priced for, and the two directions each can take.

Author Irene Q.

Oct 22, Thu

A Reuters poll run October 16-20 found 94 of 100 economists expecting the Fed to hold at 3.75-4.00% on October 28 — and all 100 expecting a hike in December, against less than half a month earlier. The market is close to the same price, with CME FedWatch at roughly 17% for October and 82.8% for December. With the Fed in blackout since October 17, here are the five dates that decide the rest of the year, what each one is priced for, and the two directions each can take.

Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 23, 2026 Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 23, 2026. Read on for the details.

Author Mitrade

Yesterday 02: 56

Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 23, 2026. Read on for the details.

Nasdaq closes at 26,008.86 — 8.9 points above 26,000, and the credit market never blinked The Nasdaq Composite fell 2.60% to 26,008.86 on October 22, its worst session since June, as Meta sank 6.98% on 2026 capex guidance of $135–145 billion. But the equal-weight S&P 500 rose 0.73%, high-yield credit was flat and 10-year yields fell 20 basis points. This was an AI de-rating, not a risk-off event — here is the transmission chain, the 29,000 / 28,200 levels and what would prove it wrong.

Author Irene Q.

21 hours ago

The Nasdaq Composite fell 2.60% to 26,008.86 on October 22, its worst session since June, as Meta sank 6.98% on 2026 capex guidance of $135–145 billion. But the equal-weight S&P 500 rose 0.73%, high-yield credit was flat and 10-year yields fell 20 basis points. This was an AI de-rating, not a risk-off event — here is the transmission chain, the 29,000 / 28,200 levels and what would prove it wrong.

Popular Symbols